ESMO E-Learning: Biomarkers of Anti-VEGF Therapy
- Describe the role of tumour angiogenesis as both a mechanism of disease progression and a therapeutic target in cancer
- Understand the potential role of biomarkers of antiangiogenic activity in cancer treatment
- Discuss challenges in the development of validated biomarkers of antiangiogenic activity
|Title||Duration||Content||CME Points||CME Test|
|Biomarkers of Anti-VEGF Therapy||26 min.||32 slides||1||Take Test|
Blocking vascular endothelial growth factor (VEGF) can have antivascular and normalising effects on the tumour vasculature, which may not necessarily translate into clinical responses as evaluated by criteria based on tumour size measurements. There is also a need to identify new targets to prevent the invariable escape from antiangiogenic therapies, which target specifically or primarily the VEGF pathway.
Ideally, biomarkers should be relatively easy to measure by imaging or in body fluids using standardised protocols. For plasma or serum biomarkers, this could be more easily achieved, given the multiple and reliable options to measure various proteins.
Several potentially interesting biomarkers of sensitivity or resistance to antiangiogenic treatments have been evaluated in recent translational studies. Some of them still provide controversial results and no one, to date, can be used routinely. Many of the studied biomarkers are currently under clinical investigation and validation in prospective randomised studies.
This E-Learning module focuses on translational research aimed to identify molecular, biological, and functional biomarkers for antiangiogenic therapies that can provide in the future information about dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.
The authors have reported no conflicts of interest.